Minerva Neurosciences | NERV - Current Assets


Minerva Neurosciences reported $83.1M in Current Assets for its fiscal quarter ending in December of 2025.





Current Assets Change Date
Acadia Pharmaceuticals USD 1.06B 14.31M Dec/2025
Adma Biologics USD 466.51M 63.86M Dec/2025
ALKERMES USD 1.93B 187.5M Dec/2025
Alterity Therapeutics Limited AUD 37.91M 15.92M Dec/2025
AstraZeneca USD 28.72B 1.22B Dec/2025
BioCryst Pharmaceuticals USD 404.35M 48.66M Dec/2025
Bristol-Myers Squibb USD 35.63B 2.41B Sep/2025
Cipla INR 249.18B 16.3B Sep/2025
Clal Biotechnology ILS 14.69M 1.95M Dec/2023
Compugen USD 148.02M 59.1M Dec/2025
CSL USD 11.85B 1000K Dec/2025
Eli Lilly USD 55.63B 6.44B Dec/2025
Esperion Therapeutics USD 462.57M 102.11M Dec/2025
GlaxoSmithKline GBP 17.51B 332M Dec/2025
Grifols EUR 5.96B 316.31M Dec/2025
Halozyme Therapeutics USD 825.21M 503.54M Dec/2025
Ionis Pharmaceuticals USD 2.99B 471.01M Dec/2025
J&J USD 55.62B 1.01B Dec/2025
Merck USD 47.56B 10.49B Sep/2025
Minerva Neurosciences USD 83.1M 70.08M Dec/2025
Neurocrine Biosciences USD 2.52B 364.3M Dec/2025
Novartis USD 30.46B 2.26B Dec/2025
Novavax USD 978.28M 3.69M Dec/2025
Pfizer USD 46.92B 3.22B Sep/2025
Roche Holding CHF 38.73B 3.03B Dec/2025
Sanofi EUR 30.95B 3.09B Dec/2025
Takeda JPY 3.12T 195.82B Dec/2025
Vanda Pharmaceuticals USD 347.26M 20.23M Dec/2025